5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

The purpose of this phase I, dose-escalation study was to determine the toxicity, maximum tolerated dose, pharmacokinetics, and pharmacodynamic end points of 5,6-dimethylxanthenone acetic acid (DMXAA). In all, 46 patients received a total of 247 infusions of DMXAA over 15 dose levels ranging from 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Rustin, G J S, Bradley, C, Galbraith, S, Stratford, M, Loadman, P, Waller, S, Bellenger, K, Gumbrell, L, Folkes, L, Halbert, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747563/
https://www.ncbi.nlm.nih.gov/pubmed/12698178
http://dx.doi.org/10.1038/sj.bjc.6600885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747563/
https://www.ncbi.nlm.nih.gov/pubmed/12698178
http://dx.doi.org/10.1038/sj.bjc.6600885

Ejemplares similares